The global medical technology industry continues to evolve, driven by aging populations, rising chronic disease prevalence, expanding access to minimally invasive procedures and advances in medical imaging, robotics and AI-assisted healthcare. Within this market, Boston Scientific has established itself as a major player in cardiovascular intervention, electrophysiology, endoscopy, urology and neuromodulation.
Boston Scientific generated $20.074 billion in revenue in FY2025, representing 19.9% reported growth and 15.8% organic growth. However, its performance moderated considerably in 2026: the company reported $5.138 billion in Q3 2026 revenue, up 1.5% organically year over year, and revised its full-year 2026 organic sales growth outlook to approximately 3.75%.
Boston Scientific competes with companies ranging from diversified medical technology groups such as Medtronic and Abbott to specialists such as Edwards Lifesciences, Intuitive Surgical and Olympus. The nature of the competition varies significantly: some companies offer directly competing devices, while others supply the imaging systems, surgical platforms or hospital technologies used alongside Boston Scientific products.
This guide examines important competitors and adjacent players, covering their financial scale, product portfolios, areas of overlap and competitive positioning.
What Makes Boston Scientific a MedTech Leader?
Founded in 1979, Boston Scientific developed its business around less invasive medical technologies for cardiovascular disease. Over time, acquisitions and product innovation expanded its portfolio into electrophysiology, structural heart, peripheral intervention, endoscopy, urology and neuromodulation.
Its product portfolio includes coronary stents, cardiac ablation systems, implantable defibrillators, left atrial appendage closure devices, prostate treatment systems, spinal cord stimulation devices and therapeutic endoscopy products. This gives the company relationships with cardiologists, electrophysiologists, urologists, gastroenterologists and pain specialists.
Several products are particularly important to its competitive position. WATCHMAN FLX is a major product in left atrial appendage closure, while FARAPULSE has strengthened Boston Scientific’s position in pulsed-field ablation for atrial fibrillation.
Its urology portfolio includes Rezūm water-vapor therapy for benign prostatic hyperplasia and Optilume drug-coated balloon technology. In neuromodulation, the WaveWriter Alpha spinal cord stimulation platform competes in the chronic pain treatment market.
Boston Scientific’s recent financial performance, however, should be viewed in the context of its changing growth trajectory. FY2025 was exceptionally strong, but Q3 2026 growth slowed following operational challenges, including a cybersecurity incident that affected business operations.
The company has also announced an agreement to acquire Penumbra, a specialist in thrombectomy and embolization technologies. The proposed transaction, announced in January 2026, has an enterprise value of approximately $14.5 billion and would expand Boston Scientific into neurovascular and peripheral vascular intervention.
As of October 30, 2026, the acquisition remains pending. It should therefore be considered a potential expansion of Boston Scientific’s competitive footprint rather than an already integrated business.
Top Boston Scientific Competitors & Alternatives
1. Medtronic
Medtronic is one of Boston Scientific’s broadest and most direct competitors. Founded in 1949 and headquartered in Ireland, the company operates across cardiovascular devices, cardiac rhythm management, neuromodulation, surgical technologies and diabetes-related medical technology.
Medtronic reported FY2026 revenue of approximately $36.4 billion, up 8.4% on a reported basis and 5.8% organically. Its cardiovascular portfolio competes with Boston Scientific in cardiac ablation, structural heart, coronary intervention and rhythm management.
Its products include the Arctic Front cryoballoon ablation system, Evolut transcatheter aortic valve replacement platform, LINQ insertable cardiac monitors and a broad range of cardiac rhythm management devices. These products compete with Boston Scientific’s electrophysiology, structural heart and cardiac monitoring portfolio.
Medtronic is also developing its Hugo robotic-assisted surgery platform, which targets soft-tissue procedures. Although this is not a direct substitute for most Boston Scientific devices, it demonstrates Medtronic’s expansion into technology-enabled surgical procedures.
Medtronic’s scale provides advantages in global distribution, physician training, hospital relationships and procurement negotiations. Its broad portfolio makes it one of Boston Scientific’s most significant competitors across multiple clinical categories.
2. Abbott Laboratories
Abbott is a diversified healthcare company with businesses spanning medical devices, diagnostics, nutrition and established pharmaceuticals. It competes with Boston Scientific most directly in electrophysiology, cardiac rhythm management, neuromodulation and selected vascular intervention categories.
Abbott reported total revenue of approximately $44.3 billion in FY2025. Its Medical Devices business is particularly important, with strong growth from its FreeStyle Libre continuous glucose monitoring franchise and cardiovascular technologies.
Abbott’s acquisition of St. Jude Medical in 2017 significantly expanded its cardiovascular portfolio. The acquisition brought cardiac rhythm management products, electrophysiology technologies, heart failure devices and neuromodulation capabilities into Abbott’s business.
In electrophysiology, Abbott’s EnSite X cardiac mapping system competes with Boston Scientific’s Rhythmia HDx mapping platform. Abbott’s TactiFlex and other ablation catheters also compete in the treatment of atrial fibrillation and other cardiac arrhythmias.
Abbott’s Proclaim spinal cord stimulation systems compete with Boston Scientific’s WaveWriter Alpha portfolio in chronic pain management. Its structural heart and vascular technologies also overlap with selected Boston Scientific products.
Abbott’s FreeStyle Libre system is a major business but does not directly compete with Boston Scientific’s core portfolio. It demonstrates the breadth of Abbott’s medical technology operations rather than a direct competitive overlap.
3. Johnson & Johnson
Johnson & Johnson is a major competitor in medical technology through its MedTech business, which includes cardiovascular products, electrophysiology, surgery, orthopedics and vision-related technologies.
J&J MedTech generated approximately $33.8 billion in FY2025 revenue, up 6.1% operationally. Its cardiovascular portfolio expanded through acquisitions, including Abiomed and Shockwave Medical, while its electrophysiology business remains an important competitive area.
The company’s Biosense Webster division is a major player in electrophysiology mapping and ablation. Its CARTO 3 mapping system competes directly with Boston Scientific’s Rhythmia HDx platform in cardiac mapping laboratories.
Biosense Webster also offers a broad range of ablation catheters and related electrophysiology technologies. These products compete with Boston Scientific’s FARAPULSE and other cardiac ablation solutions.
J&J’s Ethicon business is another important part of its surgical portfolio, offering staplers, sutures, energy devices and instruments for minimally invasive procedures. These products compete in broader surgical procurement categories, although they are not direct substitutes for most Boston Scientific endoscopy products.
J&J is also developing the OTTAVA robotic surgical system for soft-tissue procedures. The system represents a potential competitive force in robotic surgery, but it should not be treated as an established commercial rival across Boston Scientific’s current device categories.
J&J’s combination of Biosense Webster’s electrophysiology capabilities and Ethicon’s surgical portfolio makes it a significant competitor in selected cardiovascular and surgical markets.
4. Stryker Corporation
Stryker is a major medical technology company best known for orthopedics, surgical equipment, neurotechnology and medical devices. It competes with Boston Scientific most directly in neurovascular intervention, particularly through its Neurovascular business.
Stryker reported approximately $25.1 billion in FY2025 revenue, with growth of around 11.2%. Its Neurovascular division manufactures products for ischemic and hemorrhagic stroke treatment, including thrombectomy systems, embolization coils and flow-diversion technologies.
Boston Scientific’s proposed acquisition of Penumbra would create a more direct competitive overlap with Stryker in thrombectomy and neurovascular intervention. Penumbra’s aspiration and mechanical thrombectomy products would expand Boston Scientific’s presence in a category where Stryker already has an established business.
Stryker’s surgical portfolio also includes visualization systems, powered instruments and the Mako robotic-arm assisted surgery platform. These products compete in broader hospital equipment and operating-room budgets, but they are not direct substitutes for Boston Scientific’s cardiovascular and gastrointestinal devices.
Stryker’s strong hospital relationships, commercial infrastructure and acquisition strategy make it an important competitor in selected clinical markets. Its neurovascular business is particularly relevant to Boston Scientific’s proposed expansion through Penumbra.
5. Becton, Dickinson and Company (BD)
Becton, Dickinson and Company, commonly known as BD, is a diversified medical technology company operating in medication delivery, diagnostics, biosciences and interventional medical products. Its portfolio overlaps with Boston Scientific in selected peripheral vascular and urology categories.
BD’s acquisition of C.R. Bard in 2017 significantly expanded its presence in vascular access, peripheral intervention, urology and oncology-related medical devices. Bard’s portfolio brought BD closer to Boston Scientific in several hospital-based procedural markets.
In peripheral vascular intervention, BD’s Lutonix drug-coated balloon technology competes in the treatment of peripheral arterial disease. Boston Scientific offers competing technologies such as Ranger drug-coated balloons and Eluvia drug-eluting stents.
In urology, BD sells catheters, ureteral stents and other devices used in urinary care. These products overlap with selected parts of Boston Scientific’s urology portfolio, although the companies do not offer identical product ranges.
BD’s broader medication management and infusion businesses also compete for hospital procurement budgets. However, these should be distinguished from Boston Scientific’s core interventional medical device categories.
BD has been restructuring its portfolio, including the planned separation of its Biosciences and Diagnostic Solutions businesses through a transaction involving Waters Corporation. This may change its future business mix and competitive focus.
6. Intuitive Surgical
Intuitive Surgical is one of the most influential companies in robotic-assisted surgery. Its da Vinci surgical systems are used in urology, gynecology, thoracic surgery and general surgery, making it an important player in the broader minimally invasive procedure market.
Intuitive reported approximately $10.1 billion in FY2025 revenue, representing 21% growth. The number of procedures performed using its da Vinci systems increased approximately 18% to around 3.15 million.
Its da Vinci 5 platform represents a major advancement in robotic-assisted surgery, offering enhanced computing capabilities and additional surgical insights. The company also operates the Ion robotic bronchoscopy platform for minimally invasive lung biopsy procedures.
The Ion system is relevant to Boston Scientific’s pulmonary portfolio. However, the original comparison between Ion and Boston Scientific’s EXALT Model D was incorrect: EXALT Model D is a single-use duodenoscope, not a bronchoscope.
The more relevant comparison is between Intuitive’s Ion robotic bronchoscopy platform and Boston Scientific’s EXALT Model B single-use bronchoscope. These technologies address different aspects of bronchoscopy and biopsy workflows, so the competition is not a straightforward one-to-one product comparison.
Intuitive’s robotic systems also compete for hospital capital budgets and influence how minimally invasive procedures are performed. Its growth demonstrates the increasing importance of robotics in surgical care, even where direct product overlap with Boston Scientific is limited.
7. Siemens Healthineers
Siemens Healthineers is a global medical technology company specializing in diagnostic imaging, laboratory diagnostics and image-guided therapy. Its products are widely used in hospitals and interventional procedure suites where Boston Scientific devices are deployed.
The company’s ARTIS family of angiography systems provides imaging infrastructure for cardiac catheterization laboratories, vascular procedures and hybrid operating rooms. These systems support the use of catheters, stents and other interventional devices manufactured by companies such as Boston Scientific.
This creates a largely complementary relationship rather than direct product competition. Siemens supplies the imaging equipment that helps clinicians guide procedures, while Boston Scientific supplies many of the devices used during those procedures.
Siemens Healthineers also owns Varian, which provides radiation oncology technologies. Its AI-assisted imaging and diagnostic capabilities strengthen its position in hospital technology and clinical workflow management.
The company’s importance to Boston Scientific lies in its influence over hospital imaging infrastructure, capital expenditure and image-guided treatment ecosystems. It should therefore be considered an adjacent technology competitor rather than a direct rival across most Boston Scientific product categories.
8. Edwards Lifesciences
Edwards Lifesciences is one of Boston Scientific’s most direct competitors in structural heart intervention. The company specializes in transcatheter heart valve technologies, surgical structural heart products and critical care monitoring.
Edwards reported FY2025 revenue of approximately $6.1 billion, with sales growing 11.5%. Its SAPIEN family of transcatheter aortic valve replacement systems is a major platform in the treatment of severe aortic stenosis.
Boston Scientific competes with Edwards through its ACURATE neo2 and ACURATE Prime transcatheter aortic valve systems. The companies compete for physicians, hospitals and patients in the TAVR market, where clinical evidence, device performance, delivery systems and procedural outcomes are important differentiators.
Edwards is also expanding its transcatheter mitral and tricuspid therapies business. Its EVOQUE tricuspid valve replacement system and PASCAL repair system address structural heart conditions beyond aortic valve disease.
This expansion gives Edwards a strong position in emerging structural heart markets. Boston Scientific’s portfolio has a more limited presence in these specific therapies, making Edwards a particularly important competitor in TAVR and a significant player in adjacent structural heart categories.
9. Zimmer Biomet
Zimmer Biomet is a global orthopedic medical technology company specializing in hip and knee replacement, spine technologies, sports medicine and robotic-assisted surgery. Its competitive overlap with Boston Scientific is limited and mostly indirect.
Zimmer Biomet reported approximately $8.23 billion in FY2025 revenue, up 7.2% on a reported basis. Its portfolio includes orthopedic implants, surgical instruments and the ROSA robotic surgery platform.
ROSA supports robotic-assisted procedures in areas such as knee replacement and spine surgery. It competes more directly with Stryker’s Mako and other orthopedic robotic platforms than with Boston Scientific’s core cardiovascular or endoscopy devices.
Zimmer Biomet’s spine products address structural spinal conditions, while Boston Scientific’s WaveWriter Alpha spinal cord stimulation system treats chronic pain through neuromodulation. These approaches may be considered within the same broader patient-care pathway, but they are not interchangeable products.
Zimmer Biomet is therefore best viewed as an adjacent competitor in hospital budgets, spine-care pathways and surgical technology rather than a major direct Boston Scientific rival.
10. Philips Healthcare
Philips is a global health technology company focused on diagnostic imaging, image-guided therapy, patient monitoring and connected care. Its portfolio overlaps with Boston Scientific mainly through the imaging and clinical infrastructure used in interventional procedures.
Philips’ Azurion image-guided therapy platform is widely used in cardiac catheterization laboratories and other interventional settings. It provides imaging and procedural guidance for clinicians using cardiovascular devices from manufacturers such as Boston Scientific.
Philips also offers patient monitoring technologies, including its IntelliVue range. These systems are used in hospitals and intensive care settings, where monitoring and clinical data management are important components of patient care.
The company’s HealthSuite ecosystem and connected-care technologies support hospital workflows and data integration. These products compete for healthcare technology budgets but do not directly replace most Boston Scientific interventional devices.
Philips has also been addressing the consequences of its major respiratory device recall. Its recovery, product innovation and focus on image-guided therapy remain important factors in the wider medical technology market.
11. Smith+Nephew
Smith+Nephew is a UK-based medical technology company focused on orthopedics, sports medicine and advanced wound management. Its competitive overlap with Boston Scientific is relatively limited and is concentrated in broader minimally invasive procedure and hospital procurement markets.
Its Sports Medicine business offers arthroscopic instruments, visualization technologies and soft-tissue repair products used in orthopedic procedures. These products compete with other sports medicine specialists, including Stryker and Arthrex, rather than directly with most of Boston Scientific’s gastrointestinal endoscopy portfolio.
Smith+Nephew’s CORI surgical system supports robotic-assisted knee replacement procedures. Its wound management products include ALLEVYN dressings and PICO negative pressure wound therapy systems.
These products serve clinical needs that are largely outside Boston Scientific’s main cardiovascular, urology and endoscopy businesses. Smith+Nephew is therefore an adjacent medical technology competitor, not one of Boston Scientific’s most direct rivals.
Its importance in this comparison comes from its hospital relationships, international distribution network and participation in the broader minimally invasive surgery market.
12. Hologic
Hologic is a specialist medical technology company focused on women’s health, breast health, diagnostics and surgical products. It competes with Boston Scientific in selected gynecological procedures, particularly endometrial ablation.
Hologic’s NovaSure system is used to treat abnormal uterine bleeding through endometrial ablation. Boston Scientific has historically competed in this area through technologies such as Genesys HTA and its gynecological endoscopy portfolio.
The competitive landscape in this category is shaped by clinical outcomes, procedure economics, physician preferences and the availability of alternative treatments. Product availability and commercial status should be checked by market before making claims about current head-to-head competition.
Hologic’s breast health business includes 3D mammography, breast biopsy systems and diagnostic technologies. Its Panther and Aptima platforms are used in molecular diagnostics.
These businesses do not directly compete with Boston Scientific’s core cardiovascular and interventional products. Hologic is best regarded as a focused competitor in women’s health and selected minimally invasive gynecological procedures.
13. GE HealthCare
GE HealthCare became an independent publicly traded company in January 2023 following its separation from General Electric. Its portfolio includes medical imaging, ultrasound, patient care solutions and pharmaceutical diagnostics.
The company’s interventional imaging systems, including its Innova platforms, are used in cardiac catheterization laboratories and vascular procedure suites. These systems provide imaging support for clinicians using Boston Scientific’s catheters, stents and other interventional devices.
GE HealthCare’s ultrasound products, including the LOGIQ and Venue families, are used across cardiac, vascular and point-of-care settings. Its Edison platform supports AI-enabled imaging and clinical workflow applications.
Like Siemens Healthineers and Philips, GE HealthCare is primarily an infrastructure and technology ecosystem provider to Boston Scientific’s interventional business. Its competitive influence is strongest in hospital imaging budgets, digital workflows and image-guided procedure environments.
14. Olympus Corporation
Olympus is one of the world’s leading manufacturers of gastrointestinal endoscopes and related medical technologies. Its endoscopy portfolio is highly relevant to Boston Scientific because many Boston Scientific therapeutic devices and accessories are used during procedures performed with Olympus endoscopes.
Olympus manufactures reusable gastrointestinal endoscopes, endoscopic imaging systems and a range of therapeutic devices. Boston Scientific competes in the broader endoscopy market through products such as biopsy forceps, hemostasis clips, stents, lithotripsy devices and other therapeutic accessories.
The relationship is partly complementary: Olympus supplies the endoscope platform, while Boston Scientific supplies devices used through or alongside those platforms. Competition occurs in selected therapeutic device categories and in the broader purchasing decisions of endoscopy departments.
Single-use endoscopy is an important area of competition. Boston Scientific’s EXALT Model D is a single-use duodenoscope, while Olympus has also developed disposable endoscopy technologies.
In bronchoscopy, Boston Scientific’s EXALT Model B single-use bronchoscope competes in a market where Olympus has established reusable endoscope products. The trade-offs include infection control, device cost, image quality, procedural requirements and the economics of reusable versus disposable equipment.
Olympus is therefore one of Boston Scientific’s most relevant competitors in endoscopy, although the two companies do not compete directly across every product category.
15. Baxter International
Baxter International is a medical technology company focused on hospital products, infusion therapies, clinical nutrition and other essential healthcare technologies. Its competitive overlap with Boston Scientific is limited and largely indirect.
Following the separation of its renal care business into Vantive in 2025, Baxter’s portfolio became more concentrated around hospital products and therapies. Its offerings include intravenous solutions, infusion systems, medication delivery products and related hospital technologies.
Baxter’s SIGMA Spectrum infusion pump platform competes in the hospital infusion market. These devices are used to deliver medications and fluids in clinical settings, including hospitals where Boston Scientific’s interventional procedures are performed.
However, infusion pumps and intravenous solutions are not direct substitutes for Boston Scientific’s cardiovascular, endoscopy or neuromodulation devices. Baxter is better understood as a participant in the broader hospital technology and procurement ecosystem.
Its scale, hospital relationships and product distribution network make it relevant to the wider healthcare market, but it is not one of Boston Scientific’s closest direct competitors.
16. Artivion (Formerly CryoLife)
Artivion, formerly known as CryoLife, specializes in aortic surgery, cardiac surgery and aortic stent graft technologies. Its portfolio includes surgical grafts, stent grafts and preserved human tissue products used in complex cardiovascular procedures.
The company reported FY2025 revenue of approximately $441.3 million, making it considerably smaller than Boston Scientific. Its specialist focus, however, gives it an important position in selected aortic surgery and endovascular treatment categories.
Artivion’s products include the AMDS hybrid prosthesis for aortic arch repair and the E-nya stent graft platform. Boston Scientific’s Relay and other vascular technologies address selected aortic and peripheral vascular treatment markets.
The two companies may compete in particular aortic intervention categories, although their product portfolios and clinical indications are not identical. Technical performance, physician experience and long-term clinical outcomes are important factors in this specialist market.
Artivion is therefore a niche competitor rather than a broad medical technology rival. Its significance comes from its specialization in complex aortic procedures and its relationships with cardiovascular and cardiothoracic surgeons.
Emerging Competitors and MedTech Disruptors
Beyond established medical device companies, Boston Scientific faces potential disruption from smaller technology companies developing new diagnostic, monitoring and treatment approaches. These companies do not all compete directly with Boston Scientific today, but some could influence future clinical pathways.
Butterfly Network develops handheld ultrasound devices that make point-of-care imaging more accessible. Its technology could influence how clinicians screen and assess patients, although it does not directly replace Boston Scientific’s structural heart or interventional devices.
Guardant Health develops blood-based cancer testing and precision oncology technologies. Its tests may influence cancer screening and diagnostic pathways, but they are not direct substitutes for Boston Scientific’s endoscopy products.
Neuralink and other brain-computer interface developers are exploring new ways to connect neural activity with external devices. These technologies are still developing and should be treated as a long-term adjacent innovation area rather than an established competitor to Boston Scientific’s spinal cord stimulation portfolio.
Other emerging companies are developing technologies for outpatient procedures, remote monitoring, AI-assisted diagnostics and minimally invasive treatment. Their impact may come from changing how patients are diagnosed, where procedures are performed and which technologies clinicians choose.
The common theme is that new technologies can change clinical pathways and procedure volumes. However, claims that these innovations will replace Boston Scientific’s existing businesses should be treated as forward-looking possibilities, not established market outcomes.
Boston Scientific’s response includes internal research and development, product innovation and strategic acquisitions. Its proposed Penumbra acquisition is an example of expanding into an adjacent high-growth market through an established specialist rather than building an entirely new business organically.
Boston Scientific vs. Its Competitors: At-a-Glance
The table below uses the latest completed annual financial figures identified for each company. Reporting periods differ, and some figures represent total company revenue while others refer to a specific business segment; they should not be interpreted as a direct ranking of competing product businesses.
| Company | Latest annual revenue shown | Main area of overlap with Boston Scientific |
|---|---|---|
| Boston Scientific | $20.07B (FY2025) | Cardiovascular, EP, endoscopy, urology and neuromodulation |
| Medtronic | $36.36B (FY2026) | Cardiac ablation, rhythm management, structural heart and neuromodulation |
| Abbott Laboratories | $44.33B (FY2025, total company) | Electrophysiology, cardiac devices and neuromodulation |
| Johnson & Johnson | $33.79B (FY2025, MedTech segment) | Electrophysiology, cardiovascular and surgical devices |
| Stryker | Approximately $25.1B (FY2025) | Neurovascular intervention and selected surgical technologies |
| BD | Approximately $21.8B (FY2025) | Peripheral vascular, urology and medication delivery |
| Intuitive Surgical | $10.1B (FY2025) | Robotic surgery and robotic bronchoscopy |
| Siemens Healthineers | Approximately €21.8B (FY2025) | Image-guided therapy and cath lab imaging |
| Edwards Lifesciences | Approximately $6.1B (FY2025) | Structural heart and TAVR |
| Zimmer Biomet | $8.23B (FY2025) | Adjacent spine and surgical technology markets |
| Philips | Approximately €18B–€19B (FY2025) | Image-guided therapy and patient monitoring |
| Smith+Nephew | Approximately $6.2B (FY2025) | Adjacent minimally invasive surgery and sports medicine |
| Hologic | Approximately $4.1B (FY2025) | Women’s health and gynecological procedures |
| GE HealthCare | Approximately $19B–$20B (FY2025) | Cath lab imaging and image-guided intervention |
| Olympus | Approximately ¥1.0T (FY2026) | Gastrointestinal endoscopy |
| Baxter International | Verify latest continuing-operations figure | Hospital products and infusion systems |
| Artivion | $441.3M (FY2025) | Aortic surgery and endovascular repair |
Note: These figures use different fiscal year-end dates and reporting definitions. Abbott’s figure is total company revenue, while J&J’s is MedTech segment revenue. Olympus reports in Japanese yen. Boston Scientific’s FY2025 revenue is included as the annual baseline; its latest Q3 2026 results are discussed separately.
Navigating the MedTech Competitive Landscape
Boston Scientific does not face a single competitor across its entire business. Instead, the competitive landscape changes according to the clinical specialty, device category and procedure being considered.
In electrophysiology and cardiac ablation, its main competitors include Medtronic, Abbott and Johnson & Johnson’s Biosense Webster. In structural heart and TAVR, Edwards Lifesciences and Medtronic are important competitors.
In endoscopy, Olympus is a major competitor in endoscope platforms, while Boston Scientific competes in therapeutic accessories, stents and single-use devices. In neuromodulation, Medtronic and Abbott are among its most relevant rivals.
In neurovascular intervention, Stryker and Medtronic are important competitors to Penumbra. If Boston Scientific completes its proposed acquisition of Penumbra, this category will become a more direct part of its competitive landscape.
Imaging companies such as Siemens Healthineers, Philips and GE HealthCare have a different role. Their systems often support the procedures in which Boston Scientific devices are used, making them ecosystem participants and hospital technology competitors rather than direct device substitutes.
For hospital procurement teams, important differentiators include clinical outcomes, safety, device economics, physician training, service infrastructure and compatibility with existing hospital systems. Single-use versus reusable device economics are also increasingly important in selected endoscopy procedures.
Investors should monitor Boston Scientific’s organic revenue growth, product-level performance, margins, cash generation and acquisition integration. The company’s proposed Penumbra acquisition could expand its addressable market, but its financial and commercial impact will depend on closing, integration and future performance.
Frequently Asked Questions
1. Who is Boston Scientific’s biggest competitor?
Medtronic is one of Boston Scientific’s broadest competitors by revenue and product portfolio. It competes in cardiovascular devices, cardiac ablation, structural heart and neuromodulation.
However, the leading competitor varies by category. Edwards Lifesciences is a major competitor in TAVR, Johnson & Johnson’s Biosense Webster competes in electrophysiology mapping, and Olympus is a major player in gastrointestinal endoscopy.
2. How does Boston Scientific’s revenue compare with Medtronic?
Boston Scientific reported $20.074 billion in FY2025 revenue, while Medtronic reported approximately $36.4 billion in FY2026 revenue. Medtronic is therefore larger by total revenue, although the figures cover different fiscal periods.
Boston Scientific delivered stronger growth in FY2025, but its growth moderated substantially in 2026. Medtronic’s FY2026 organic revenue growth was 5.8%, while Boston Scientific’s Q3 2026 organic growth was 1.5%.
3. Does Boston Scientific compete with Intuitive Surgical?
The overlap is primarily in minimally invasive procedures and bronchoscopy. Intuitive’s Ion robotic bronchoscopy system and Boston Scientific’s EXALT Model B single-use bronchoscope serve related clinical workflows, although they use different technologies.
Intuitive’s da Vinci robotic surgery systems also influence how minimally invasive procedures are performed, but they are not direct substitutes for most Boston Scientific devices.
4. What is Boston Scientific’s position in structural heart?
Boston Scientific competes in transcatheter aortic valve replacement through its ACURATE neo2 and ACURATE Prime systems. Its major competitors include Edwards Lifesciences’ SAPIEN family and Medtronic’s Evolut platform.
Boston Scientific is also a major participant in left atrial appendage closure through WATCHMAN FLX. This is a different structural heart category from TAVR and has its own competitive landscape.
5. Why is Boston Scientific acquiring Penumbra?
The proposed acquisition of Penumbra would expand Boston Scientific’s presence in thrombectomy, neurovascular intervention and embolization technologies. Penumbra’s portfolio would add products used in the treatment of stroke and other vascular conditions.
The transaction was announced in January 2026 at an enterprise value of approximately $14.5 billion. As of October 30, 2026, it remains pending and should not be described as a completed acquisition.
6. How does Boston Scientific compete with Abbott in electrophysiology?
Both companies offer technologies for cardiac mapping and ablation. Abbott’s EnSite X mapping platform competes with Boston Scientific’s Rhythmia HDx system, while their respective catheter portfolios compete in cardiac ablation.
Boston Scientific’s FARAPULSE pulsed-field ablation system is an important product in this category. Abbott also participates in the growing pulsed-field ablation market, so competition should be assessed across the complete product portfolios rather than treating one company as the only provider.
7. Does Boston Scientific compete with Olympus?
Yes, particularly in gastrointestinal endoscopy and selected therapeutic devices. Olympus is a major manufacturer of reusable endoscopes, while Boston Scientific sells therapeutic accessories, stents and other devices used in endoscopic procedures.
They also compete in selected single-use endoscopy categories. Boston Scientific’s EXALT Model D is a single-use duodenoscope, while its EXALT Model B is a single-use bronchoscope.
8. What is Boston Scientific’s key competitive advantage?
Boston Scientific’s main strengths include its broad minimally invasive device portfolio, established physician relationships, product innovation and presence across several high-value clinical specialties.
WATCHMAN FLX and FARAPULSE are important products in its cardiovascular portfolio, while Rezūm and Optilume strengthen its urology business. The company’s ability to develop new technologies and expand through acquisitions also supports its competitive positioning.
9. How does global medical device market growth affect Boston Scientific?
The medical device industry benefits from long-term demand drivers such as aging populations, chronic disease prevalence, technological innovation and wider access to minimally invasive treatment.
Boston Scientific participates in several attractive categories, including cardiac ablation, structural heart intervention, endoscopy and neuromodulation. However, market growth does not automatically translate into higher company revenue; competitive performance, pricing, reimbursement, clinical evidence and product adoption also matter.
10. Can Boston Scientific sustain its 15–20% growth rate?
Boston Scientific’s FY2025 organic revenue growth was 15.8%, but its Q3 2026 organic growth was only 1.5%. Its FY2026 organic revenue growth outlook was approximately 3.75% as of October 28, 2026.
The company therefore should not be assumed to sustain a 15–20% growth rate in the near term. Future performance will depend on product adoption, recovery from operational disruptions, market competition, new product launches and the potential integration of Penumbra.
Conclusion
Boston Scientific is one of the major companies in global medical technology, with a portfolio spanning cardiovascular intervention, electrophysiology, structural heart, endoscopy, urology and neuromodulation. Its FY2025 revenue of $20.074 billion and organic growth of 15.8% demonstrated strong commercial momentum, although growth moderated significantly during 2026.
The competitive landscape is fragmented and varies by clinical category. Medtronic, Abbott and Johnson & Johnson challenge Boston Scientific across several cardiovascular and electrophysiology markets, while Edwards Lifesciences is a major competitor in TAVR and Olympus is important in gastrointestinal endoscopy.
Other companies, including Intuitive Surgical, Siemens Healthineers, Philips and GE HealthCare, influence the broader procedural and hospital technology environment. Their products may complement Boston Scientific devices in many settings rather than directly replace them.
The proposed Penumbra acquisition is an important strategic development that could expand Boston Scientific into neurovascular and thrombectomy markets. However, the transaction remains pending as of October 30, 2026, and its eventual impact will depend on closing and successful integration.
Ultimately, Boston Scientific’s competitive position will depend on clinical outcomes, product innovation, physician adoption, operational execution and its ability to sustain growth across its major therapeutic categories.
Also Read: Who Challenges Medtronic? 16 Competitors Reshaping MedTech
To read more content like this, subscribe to our newsletter
Go to the full page to view and submit the form.